Analyst: Hims & Hers itself will not profit from Novo Nordisk's GLP-1s drugs
Show original
Gelonghui March 9th｜Analysts at Truist stated that Hims & Hers itself will not profit from Novo Nordisk's GLP-1s drugs, but will instead charge customers for medical service fees. These analysts said: "We expect the revenue from the drug segment to be treated as pass-through revenue, while Hims & Hers will recognize medical service fees as income." However, this does not mean that the cooperation is without benefits. The analysts noted that the company is likely to achieve significantly higher gross margins from these medical service fees, especially in cases where medical services are provided asynchronously.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$69,082.38
+2.91%
Ethereum
ETH
$2,033.71
+4.02%
Tether USDt
USDT
$1
+0.04%
BNB
BNB
$638.96
+3.48%
XRP
XRP
$1.38
+1.73%
USDC
USDC
$1
+0.02%
Solana
SOL
$86.19
+4.70%
TRON
TRX
$0.2861
-1.53%
Dogecoin
DOGE
$0.09142
+2.05%
Cardano
ADA
$0.2591
+2.60%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now